Back to News
Market Impact: 0.2
VivoSim Labs Presents New NAMkind Data At EUROTOX 2026
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
VivoSim Labs presented new NAMkind platform data at EUROTOX 2026 in Vienna, highlighting the platform's potential to predict drug toxicity using 3D human liver and intestinal tissue models. The announcement supports the company's technology-validation narrative, though the article provides no quantitative results, commercial milestones, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VIVS0.45
More News
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- AI Buildout Hits Inflation as Fed Hikes Rates
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce
- Snap Shares More Details About $2,195 Specs AR Glasses, Plus Verizon Partnership